Webinar: Management of the Maternal, Fetal and Neonatal Challenges of Rare Blood Disorders

This is a recorded version of the Webinar, Management of the Maternal, Fetal and Neonatal Challenges of Rare Blood Disorders, that was presented live on Friday, January 10, 2025. Please scroll all the way down this page to view the archived program.

Webinar Date: 1/10/2025
Estimated Time to complete: 1 hour
Format: Archived Webinar
Target Audience: 
This activity is designed for healthcare professionals, including hematologists, obstetricians, gynecologists, pediatric/adolescent gynecologists, advanced practice providers, and nurses specializing in the care of women/girls are the primary target audience to ensure optimal comprehensive care.

Faculty:
James B. Bussel, MD
Professor Emeritus of Pediatrics
Department of Pediatrics
Weill Cornell Medicine

Kenneth J. Moise Jr, MD
Professor of Women’s Health
Dell Medical School
Director, Comprehensive Fetal Care Center
Dell Children’s Medical Center

Overview:
Rare blood disorders can lead to fetal or neonatal death or severe disability, with concomitant, significant medical and psychological risks for the mother. Physicians need to know and apply new, effective approaches to diagnosis, testing, assessment to improve fetal, neonatal, and maternal outcomes.

This Webinar discusses the current best practices and the evidence-based recommendations for the diagnosis, treatment, and management of rare blood disorders during pregnancy. A special focus on the maternal and fetal considerations professionals must address, including the risk for hemolytic disease of the fetus and newborn (HDFN) and fetal neonatal alloimmune thrombocytopenia (FNAIT), in making evidence-based decisions about optimal first-and second-line management.

Learning Objectives:

• Describe and apply available options for optimally managing care in pregnancies identified to be at risk for HDFN and FNAIT.
• Explain the importance of assessing and monitoring patients for the identification of hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).
• Discuss and describe the potential maternal, fetal and neonatal consequences of FNAIT and HDFN, and the considerations professionals must address in making decisions regarding management.
• Describe new, effective approaches to diagnosis, testing, assessment to improve fetal, neonatal, and maternal outcomes.

This Webinar is supported in part through a medical education grant from Janssen.

---